FDA Updates Drug Registration Rules for Multi-Site Makers
Published Date: 7/13/2026
Proposed Rule
Summary
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
Analyzed Economic Effects
7 provisions identified: 3 benefits, 4 costs, 0 mixed.
Single registration for distributed makers
If you run a drug manufacturing business that uses a hub-and-spoke distributed manufacturing model, the FDA is proposing a new pathway that would let the whole distributed manufacturing establishment (the hub plus its DM units) register as a single establishment instead of each site registering separately. The proposal also treats adding or removing a DM unit or relocating a mobile DM unit as an expedited update to that single registration.
New quality and inspection requirements
To qualify to register as a single distributed manufacturing establishment, the FDA proposes that the hub and its DM units must operate under one management with a unified pharmaceutical quality system (UPQS) and that the DME must have been subject to a preapproval inspection for at least one drug in each profile class manufactured by the DME. These requirements are part of the proposed definition of a DME.
Streamlined pathway excludes unaffiliated CMOs
The proposed rule would not allow multiple unaffiliated contract manufacturing organizations (CMOs) or third-party relabelers/repackers/salvagers that are not under the manufacturer's ownership or control to use the single-registration DME pathway. Those unaffiliated third parties would need to register and list separately under current rules.
Foreign establishments must register and list
The FDA proposes to amend registration and listing rules to clarify that each foreign establishment that manufactures, repacks, relabels, or salvages a drug that is imported or offered for import into the United States must register and provide drug listing information, regardless of whether the drug is further processed at a different foreign establishment before import. This change aligns the regulations with section 2511 of the PREVENT Pandemics Act.
Greater supply chain visibility and shortages help
The FDA says unquantified benefits of the proposal include greater visibility into the drug supply chain, which the Agency expects will help prevent and mitigate drug shortages and aid in preventing importation of adulterated or misbranded drugs.
Include similar OTC products under one DME
A DME registered under the proposed rule may manufacture non-application products (for example, over-the-counter monograph drugs) as long as each such non-application product is of the same FDA profile class as one or more drugs the DME manufactures under an approved application that describes use of a decentralized manufacturing strategy.
Estimated annualized compliance costs (FDA/industry)
FDA estimates annualized net costs of this proposal to be approximately $532,811 to $664,495 at a 7% discount rate (primary estimate $583,958), and $482,472 to $606,839 at a 3% discount rate (primary estimate $533,771). These estimates include costs to drug manufacturers for reading and understanding the rule and costs to FDA for updating submission schemas and tools.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20721, Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants; Draft Guidance for Industry; Availability
The FDA is sharing a draft plan about new food tracking rules that mostly won’t apply to certain stores and restaurants right now. If you run a retail food place or restaurant, you don’t have to worry about extra paperwork just yet, but the FDA wants your feedback by November 23, 2026. This helps them decide the final rules without causing extra costs or hassle for small businesses.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-14048, Fisheries of the Caribbean, Gulf of America, and South Atlantic; Snapper-Grouper Fishery of the South Atlantic Region; Abbreviated Framework Amendment 5
The government wants to update fishing rules for blueline tilefish in the South Atlantic to keep the fish population healthy and fishing fair. These changes affect fishermen and businesses by adjusting how much fish can be caught, based on the latest science. Comments on the plan are open until August 12, 2026, so now’s the time to speak up!
Next: 2026-14098, Endangered and Threatened Wildlife and Plants; 90-Day Findings for 10 Species
The U.S. Fish and Wildlife Service reviewed 10 species to see if they should be protected as endangered or threatened. They found 7 species might need protection and will study them more, while 3 species won’t be reviewed further. This process starts now and could lead to new protections that help wildlife and affect conservation efforts and funding over the next year.